OncoMatch/Clinical Trials/NCT06769971
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Is NCT06769971 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Ivonescimab and Cadonilimab for small cell lung cancer.
Treatment: Ivonescimab · Cadonilimab · Etoposide · Carboplatin — This is a phase II study. All patients are treatment naive extensive stage small cell lung cancer(ES-SCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of Ivonescimab and Cadonilimab in combination with chemotherapy in patients with ES-SCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic therapy
Exception: ES-SCLC patients who had received definitive chemoradiotherapy for limited-stage small-cell lung cancer but had disease progression > 6 months earlier
Had not received previous systemic therapy; Or ES-SCLC patients who had received definitive chemoradiotherapy for limited-stage small-cell lung cancer but had disease progression > 6 months earlier
Cannot have received: immunotherapy targeting tumor immunity
Subjects who received any prior treatments targeting the mechanism of tumor immunity
Cannot have received: anti-angiogenic therapy
Subjects who received any prior anti-angiogenic therapy
Cannot have received: palliative local treatment
Received palliative local treatment within 2 weeks prior to the first dose
Cannot have received: non-specific immunomodulatory treatment
non-specific immunomodulatory treatment within 2 weeks prior to the first dose
Cannot have received: Chinese herbal medicine or traditional Chinese medicinal products with anti-tumor indications
Chinese herbal medicine or traditional Chinese medicinal products with anti-tumor indications within 1 weeks prior to the first dose
Lab requirements
Blood counts
Kidney function
Liver function
Have adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06769971 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy, immunotherapy targeting tumor immunity, anti-angiogenic therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify